Teduglutide

替度格鲁肽

Report date: 2024/02/23 17:41:22
First In Class

Base Information

Drug NameTeduglutide
Drug Alias Nameteduglutida替度鲁肽teduglutidum特度鲁肽Gattex +[10] 
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 2 receptor agonists
TargetsGlucagon-like peptide 2 receptor
Therapy Area/IndicationsFistulaGraft vs Host DiseaseHyperlipidemias +[9] 
Global Approved IndicationsShort Bowel SyndromeMalabsorption Syndromes
Approved Indications in ChinaShort Bowel Syndrome
Original Approved Country/TerritoryEU
Original Approved Date2012/08/30
Country/TerritoryBelgiumCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShire Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesTakeda (China) International Trading Co LtdShireTakeda Pharmaceuticals USA Inc +[8] 
Inactive CompaniesRagon Institute Of Mgh, Mit And HarvardUniversity Of FreiburgNycomed
Active IndicationsFistulaHyperlipidemiasShort Bowel Syndrome +[4] 
Inactive IndicationsGraft vs Host DiseaseRenal InsufficiencyHepatic Insufficiency +[5] 

Other Information

ATC CodeA16AX08
Related LinksWikipediaDrugBankKEGG